FindTrial
Sign In

Effect of myeloperoxidase on contrast-induced nephropathy after PCI in patients with acute myocardial infarction

Effect of myeloperoxidase on contrast-induced nephropathy after PCI in patients with acute myocardial infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900020824
Enrollment
Unknown
Registered
2019-01-20
Start date
2019-02-01
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast induced nephropathy

Interventions

Case series:N//A

Sponsors

Department of Cardiology, Zhongda Hospital of Southeast University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed as acute myocardial infarction; 2. Aged 18 to 80 years; 3. PTCA or stent implantation.

Exclusion criteria

Exclusion criteria: 1. No PTCA or PCI treatment was performed; 2. End-stage renal disease requiring dialysis; 3. Known allergy to contrast agent; 4. Intravascular administration of contrast medium within 7 days; 5. Being accompanied with other diseases including autoimmune diseases, hepatic insufficiency, malignant tumor, and hematology disease.

Design outcomes

Primary

MeasureTime frame
Primary Outcome Measures:The incedence of CIN;Myeloperoxidase;—

Countries

China

Contacts

Public ContactTang Chengchun

Department of Cardiology, Zhongda Hospital of Southeast University Medical School

tangchengchun@hotmil.com+86 13914705570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026